Market Signal Briefing

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

Investors have until January 2, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in CarMax securities. The case is pending in the U.S. District Court for the District of Maryland and is captioned Jason Cap v. CarMax, Inc., et al., No. 1:25-cv-03602.

Why is CarMax Being Sued For Securities Fraud?

CarMax sells used cars. During the relevant period, the Company touted the strong and sustainable demand for its cars, driven by factors such as a seamless customer experience.

As alleged, in truth, it appears that the announcement of U.S. tariffs imposed on cars provided a short-term boost to demand, as customers purchased cars prior to the tariffs taking effect.

BFA Law is also investigating the unexpected departure of CEO Bill Nash on November 6, 2025, and whether CarMax properly assessed or reserved for its portfolio of car loans.

Why did CarMax’s Stock Drop?

On September 25, 2025, the Company reported disappointing financial results for the second quarter of its fiscal year 2026. Specifically, CarMax announced sales declines across the board, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units. The Company also posted a disappointing second quarter net income of about $95.4 million, down from $132.8 million over the prior year. A main reason for the declines, according to CarMax, was a “pull forward” in demand into the first fiscal quarter due to the announcement of tariffs.

On this news, the price of CarMax stock dropped $11.45 per share, or roughly 20%, from $57.05 per share on September 24, 2025, to $45.60 per share on September 25, 2025.

Then, on November 6, 2025, CarMax announced the unexpected departure of CEO Bill Nash and a weak preliminary Q3 2025 outlook. On this news, the price of CarMax stock dropped over 24%.

Click here for more information: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

What Can You Do?

If you invested in CarMax you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

Investors have until December 23, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock (formerly American Depositary Shares). The class action is pending in the U.S. District Court for the Northern District of Illinois and is captioned Laborers’ District Council and Contractors’ Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018.

Why Was James Hardie Sued for Securities Fraud?

James Hardie is a producer and marketer of high-performance fiber cement building solutions. The largest application for the Company’s fiber cement building products in the United Stated and Canada is in external siding for the residential building industry.

During the relevant period, James Hardie told investors that the results of its North American fiber cement segment demonstrated its “inherent strength” and “the underlying momentum in our strategy.” The Company also stated on May 20, 2025, that it was seeing “normal stock levels” among its customers and that it was “seeing performance in the month to date as we would expect.”

As alleged, in truth, the Company’s North American sales during the relevant period were the result of inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, not sustainable customer demand as represented.

The Stock Declines as the Truth Is Revealed

On August 19, 2025, James Hardie revealed that its North American fiber cement sales declined 12% during the quarter, driven by destocking first discovered “in April through May” as customers “made efforts to return to more normal inventory levels[.]” The Company also revealed that significant inventory destocking was expected to continue to impact sales for the next several quarters. On this news, the price of James Hardie stock fell $9.79 per share, or more than 34%, from $28.43 per share on August 19, 2025, to $18.64 per share on August 20, 2025.

Click here for more information: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

What Can You Do?

If you invested in James Hardie you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

Key Takeaways LMT shares rose 4.6% in three months, trailing industry peers but beating the broader aerospace sector.Revenues grew 8.8% in Q3, aided by contracts, AI and quantum computing partnerships and solid demand.Cost overruns, labor shortages and production risks could weigh on LMT's near-term performance.
Shares of Lockheed Martin Corporation (LMT - Free Report) have surged 4.6% in the past three months, underperforming the Zacks Aerospace-Defense industry’s growth of 4.9%. However, it outperformed the broader Zacks Aerospace sector’s gain of 3.8%. It also came below the S&P 500’s return of 7.7% in the same time frame.

Image Source: Zacks Investment Research

Other industry players, such as Huntington Ingalls Industries (HII - Free Report) and General Dynamics (GD - Free Report) , have delivered a stellar performance in the past three months. Shares of HII and GD have risen 18.8% and 10.6%, respectively, in the said period.

With LMT’s recent gains, some investors may want to buy the stock. However, it’s important to check if the company’s fundamentals can support long-term growth or if the rise is only short-term. Understanding LMT’s growth outlook and risks is key to making an informed decision.

Tailwinds for LMTLMT’s recent performance appears to be supported by its strong quarterly results, strategic partnerships and notable contract wins, which have helped sustain investor confidence. In October, the company reported its third-quarter 2025 results, showing revenue growth of 8.8% and a 2.2% rise in net earnings compared with the same period last year.

In November 2025, LMT formed a strategic collaboration with PsiQuantum to advance quantum computing research and applications for aerospace and defense. This agreement marks an important step toward exploring how quantum computing can help address complex national security and aerospace challenges. It also supports the development of large-scale, fault-tolerant quantum hardware designed to deliver reliable results for critical missions.

In October 2025, LMT’s Sikorsky unit received a contract from the County of Los Angeles for two S-70i FIREHAWK helicopters. These aircraft will strengthen the county’s wildfire suppression, rescue and emergency medical service capabilities across its 4,000-square-mile area.

In the same month, the company announced a partnership with Google Public Sector to integrate Google’s generative AI technology, including its Gemini models, into the Lockheed Martin AI Factory. This collaboration will bring Google’s advanced AI tools into Lockheed Martin’s secure, on-premises and isolated environments, making them accessible to employees across the organization.

Additionally, LMT was awarded a $233 million contract to deliver IRST21 Block II systems and initial spares to the U.S. Navy and Air National Guard.

For defense contractors like LMT, a steady flow of contract wins from the Pentagon and U.S. allies for its combat-proven defense products, such as the most recent awards, serves as a major growth catalyst.

LMT’s EstimatesThe Zacks Consensus Estimate for LMT’s 2025 sales implies year-over-year growth of 4.6%, while that for 2026 sales indicates an improvement of 4.4%. The consensus estimate for its 2025 earnings implies a year-over-year decline of 22.3%, while that for 2026 earnings indicates an improvement of 33.8%.

Image Source: Zacks Investment Research

Further, the upward revision in its 2025 and 2026 earnings over the past 60 days suggests investors’ increasing confidence in this stock’s earnings generation capabilities.

Image Source: Zacks Investment Research

ValuationIn terms of valuation, LMT’s forward 12-month price-to-earnings (P/E) is 15.55X, a discount to the industry average of 29.21X. This suggests that investors will be paying a lower price than the company's expected earnings growth compared with its industry average.

Image Source: Zacks Investment Research

HII and GD are trading at a premium in comparison with LMT. HII’s forward 12-month price-to-earnings is 18.98X, while GD’s forward 12-month price-to-earnings is 20.61X.

Risks to Take Note of Before Choosing LMTLMT continues to face financial and operational challenges that may pressure its performance. Persistent labor shortages across the aerospace-defense sector pose operational risks. The 2025 Workforce Study by the Aerospace Industries Association and McKinsey found that nearly a quarter of the workforce is more than 55, while attrition remains elevated at about 14.5%. Such workforce issues may lead to production delays, cost pressures and delivery setbacks, potentially weighing on Lockheed Martin’s margins and investor sentiment.

LMT has faced notable financial setbacks on several classified contracts. During the first nine months of 2025, the company recorded losses of $950 million on an ongoing classified program at its Aeronautics business segment, $570 million on the Canadian Maritime Helicopter Program, $95 million on the Turkish Utility Helicopter Program at its RMS business segment, and $105 million of unfavorable profit adjustments on C-130 programs at the Aeronautics business segment. Any further cost overruns or performance issues could result in additional material losses, putting further pressure on the company’s future financial results.

Should You Buy LMT Stock Now?Given LMT’s discounted valuation and improving long-term growth outlook, the stock appears fairly valued with potential for steady returns. Its strong quarterly performance and strategic partnerships with firms like Google and PsiQuantum provide a positive foundation for future growth.

However, ongoing labor shortages, cost overruns on classified contracts and operational risks could weigh on near-term performance. Therefore, existing shareholders may consider holding the stock, while new investors might prefer to wait for more stability in the company’s financial and operational performance before taking a position.

LMT currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

G Mining Ventures Corp (TSX:GMIN, OTCQX:GMINF) reported third quarter 2025 gold production that rose 9% quarter over quarter to 46,360 ounces, boosted by continued strong throughput and recoveries at its Tocantinzinho Gold Mine in Brazil. 

The mining company also posted record free cash flow for the quarter of US$95.8 million, an increase of 59% from Q2 2025, on a record US$161.7 million in revenue.  

"The third quarter marked a defining period for GMIN," G Mining Ventures CEO Louis-Pierre Gignac said in a statement.  

"Tocantinzinho is now operating at steady state—delivering record production, free cash flow, and margins that position us among the lowest-cost producers in the Americas." 

G Mining Ventures generated net income for the period of US$123.8 million, or US$0.55 per share. 

The company also realized an all-in sustaining cost (AISC) per ounce of gold sold in Q3 of US$1,046, while selling its gold at an average price of US$3,114 per ounce. 

As well, G Mining Ventures reaffirmed its 2025 production guidance of 175,000 to 200,000 ounces of gold, with AISC expected to remain within the US$1,025 to $1,155 per ounce range. 

Looking ahead to Q4, the company expects to advance detailed engineering and continue early works activities at Oko West and continue environmental permitting activities at Gurupi. 

It also plans to launch a 10-kilometre drill program at Gurupi, following recent permitting advances and preparatory work completed in Q3. 

November 13, 2025 8:39 AM EST | Source: New Found Gold Corp.
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2025) - New Found Gold Corp. (TSXV: NFG) (NYSE American: NFGC) ("New Found Gold" or the "Company") and Maritime Resources Corp. ( "Maritime Resources") (TSXV: MAE) are pleased to announce that they have closed their previously announced transaction whereby New Found Gold has acquired all of the issued and outstanding shares of Maritime Resources (the "Maritime Shares"), that it does not already own, by way of a statutory plan of arrangement pursuant to Division 5 of Part 9 of the Business Corporations Act (British Columbia) (the "Transaction").

In connection with the completion of the Transaction, Allen Palmiere joined the board of directors of New Found Gold (the "Board") and Melissa Render, President of New Found Gold resigned from the Board. All the directors and officers of Maritime Resources resigned from their positions.

Keith Boyle, Chief Executive Officer and Director of New Found Gold, stated: "In less than a year, New Found Gold has transformed from an early-stage exploration company to an emerging Canadian gold producer with camp-scale exploration potential. Today we see two high-quality assets, the Queensway Gold Project and the Hammerdown Gold Project, located in a Tier 1 jurisdiction with strong synergies, come together at a time of highly favourable gold prices. Under the guidance of an experienced new Board, the Company's management team of mine builders and operators are focused on the path to production and continuing to deliver shareholder value."

"The combined Company is now producing gold; we could not have gotten to this point without the support of our local communities. For this we give our thanks and look forward to continuing this journey with you," continued Mr. Boyle.

Paul Andre Huet, Chairman of New Found Gold, stated: "I am pleased to welcome Allen Palmiere to the Board. Allen brings a depth of operational, management and finance experience to the Company and his expertise on the Maritime Resources assets is of great value. On behalf of the Board and the entire company, I would also like to thank our President, Melissa Render for her service on the Board."

Garett Macdonald, President and CEO of Maritime Resources, stated, "We are pleased with the completion of the business combination and are excited for New Found Gold as it grows into Canada's newest mid-tier gold producer. I would like to recognize the efforts of Maritime's team who demonstrated determination and creativity to develop the Hammerdown Gold Project, as well as the solid support of our shareholders, local communities and the Province of Newfoundland and Labrador these past few years."

Under the terms of the arrangement agreement entered into by New Found Gold and Maritime Resources on September 4, 2025, each holder of Maritime Shares received 0.75 of a New Found Gold common share (each whole share, a "New Found Gold Share") in exchange for each Maritime Share (the "Exchange Ratio"). Immediately upon completion of the Transaction, existing New Found Gold shareholders and former Maritime Resources shareholders held approximately 69% and 31%, respectively, of the pro forma company on a fully-diluted in-the-money basis and Maritime Resources became a wholly-owned subsidiary of New Found Gold. New Found Gold will apply for Maritime Resources to cease to be a reporting issuer under applicable Canadian securities laws and the Maritime Shares will be delisted from the TSX Venture Exchange ("TSXV").

In accordance with the plan of arrangement, each option to purchase Maritime Shares (each, a "Maritime Option") was cancelled and exchanged for a replacement option to acquire from New Found Gold such number of New Found Gold Shares equal to the product of: (A) that number of Maritime Shares that were issuable upon exercise of such Maritime Option immediately prior to the effective time of the Transaction (the "Effective Time") and (B) the Exchange Ratio, at an exercise price per New Found Gold Share equal to the quotient determined by dividing: (X) exercise price per Maritime Share at which such Maritime Option was exercisable immediately prior to the Effective Time, by (Y) the Exchange Ratio. Pursuant to the plan of arrangement, each outstanding Maritime Share purchase warrant became exercisable for New Found Gold Shares issuable on exercise and adjusted in accordance with the Exchange Ratio.

In order to receive the New Found Gold Shares in exchange for their Maritime Shares, registered Maritime Resources shareholders must complete, sign, date and return the Letter of Transmittal that was mailed to each registered Maritime Resources shareholder. The Letter of Transmittal is also available from Maritime Resources' depositary, Computershare Investor Services Inc., and online under Maritime Resources' issuer profile on SEDAR+ at www.sedarplus.ca. Non-registered Maritime Resources shareholders whose Maritime Shares are registered in the name of a broker, investment dealer, bank, trust company, trustee or other intermediary or nominee should contact that intermediary or nominee for assistance in depositing their Maritime Shares and should follow the instructions of such intermediary or nominee in order to deposit their Maritime Shares.

Further information about the Transaction is set out in Maritime Resources' management information circular dated October 1, 2025, which can be accessed online under Maritime Resources' issuer profile on SEDAR+ at www.sedarplus.ca.

Blake, Cassels & Graydon LLP acted as legal counsel to New Found Gold with respect to the Transaction. BMO Capital Markets acted as financial advisor to New Found Gold. Osler, Hoskin & Harcourt LLP acted as legal counsel to Maritime Resources with respect to the Transaction. SCP Resource Finance LP and Canaccord Genuity Corp. acted as financial advisors to the board of directors of Maritime Resources.

Allen Palmiere - Independent Director

Mr. Palmiere, a Chartered Accountant-Chartered Public Accountant by training, has over 40 years of experience in the mining industry both from a financial and operational perspective. His international experience includes South Africa, Central America, Guyana Brazil and China. Mr. Palmiere's expertise includes operations, executive management and financing, both debt and equity. Additionally, Mr. Palmiere has extensive experience in mergers and acquisitions. Mr. Palmiere's former executive positions include CEO and Chairman of the Board, HudBay Minerals Inc., Executive Chairman, Barplats Investments Ltd., Vice President, CFO, Zemex Corporation, and President and CEO, Breakwater Resources Ltd. Mr. Palmiere has also served as a director of numerous public companies. Mr. Palmiere is currently the CEO, President and a Director of Gold Resource Corporation.

Shares for Debt Transaction

The Company is pleased to announce that it has entered into a debt settlement agreement (the "Settlement Agreement") with SCP Resource Finance LLP ("SCP") to settle an aggregate amount of $3,276,712 in outstanding debt, rounded down to the nearest whole number of shares, related to the fees incurred by Maritime Resources pursuant to the terms of the letter agreement with SCP dated March 20, 2024, as amended on August 8, 2025, whereby SCP was appointed as financial advisor in connection with strategic matters related to any financing or a transaction resulting in the sale of Maritime Resources.

Pursuant to the terms of the Settlement Agreement, the Company has agreed to issue 1,085,003 New Found Gold Shares (the "Settlement Shares") at a deemed issue price of $3.02 per Settlement Share, based on the closing price of the New Found Gold Shares on the TSXV on November 12, 2025 (the "Shares for Debt Transaction"). The Board of New Found Gold has determined that the Shares for Debt Transaction is in the best interests of the Company.

Closing of the Shares for Debt Transaction is subject to customary closing conditions, including the approval of the TSXV and authorization of the NYSE American. The Settlement Shares to be issued pursuant to the Shares for Debt Transaction will be subject to a hold period of four months and one day following the date of issuance, in accordance with the applicable securities laws and TSXV policies.

About New Found Gold Corp.

New Found Gold is a well-financed advanced-stage exploration and development company that holds a 100% interest in the Queensway Gold Project ("Queensway"), as well as the recently acquired Maritime Division, where the Company is focused on bringing the Hammerdown Gold Project ("Hammerdown") into steady-state gold production. The Maritime Division includes Hammerdown, where it holds a 100% interest directly and subject to option agreements entitling it to earn 100% ownership in the Green Bay Property, which includes the former Hammerdown gold mine and the Orion gold project. The Maritime Division controls over 43,900 hectares of exploration land including the Green Bay, Whisker Valley, Gull Ridge and Point Rousse projects. Mineral processing assets in the Baie Verte mining district include the Pine Cove mill and the Nugget Pond Hydrometallurgical Gold Plant gold circuit.

The Company has completed a PEA at Queensway (see New Found Gold news release dated July 21, 2025). Recent drilling continues to yield new discoveries along strike and down dip of known gold zones, pointing to the district-scale potential of the Project that covers a +110 km strike extent along two prospective fault zones. On September 8, 2025, the Company announced it had entered into a property purchase agreement with Exploits Discovery Corp. ("Exploits") that would provide New Found Gold with a 100% interest in certain mineral claims in Newfoundland and Labrador held by Exploits (the "Claims") (see news release dated September 8, 2025). The Claims adjoin Queensway and would increase the size of Queensway by up to 33%, to a total of 234,050 hectares.

The Company's assets are located in Newfoundland and Labrador, Canada, a Tier 1 jurisdiction with excellent infrastructure and a skilled local workforce.

New Found Gold has a new Board and management team, a strong treasury and a solid shareholder base which includes cornerstone investor Eric Sprott. The Company is focused on growth and value creation.

New Found Gold Corp.
Per: "Keith Boyle"
Keith Boyle, Chief Executive Officer

Qualified Persons

The scientific and technical information disclosed in this press release related to Queensway was reviewed and approved by Melissa Render, P. Geo., President, and a Qualified Person as defined under National Instrument 43-101. Ms. Render consents to the publication of this press release by New Found Gold. Ms. Render certifies that this press release fairly and accurately represents the scientific and technical information that forms the basis for this press release.

The scientific and technical information disclosed in this press release related to the Maritime Division was reviewed and approved by Keith Boyle, P. Eng., CEO, and a Qualified Person as defined under National Instrument 43-101. Mr. Boyle consents to the publication of this press release by New Found Gold. Mr. Boyle certifies that this press release fairly and accurately represents the scientific and technical information that forms the basis for this press release.

Contact

For further information on New Found Gold, please visit New Found Gold's website at www.newfoundgold.ca, contact us through our investor inquiry form at https://newfoundgold.ca/contact/ or contact:

Fiona Childe, Ph.D., P.Geo.
Vice President, Communications and Corporate Development
Phone: +1 (416) 910-4653
Email: [email protected]

Neither the TSXV nor its Regulatory Services Provider (as that term is defined in the policies of the TSXV) nor the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward-Looking Information

This press release contains certain "forward-looking statements" within the meaning of Canadian securities legislation, including statements relating to the Transaction and the Shares for Debt Transaction and statements relating to assessments of and expectations for the combined company including production of gold and the timing thereof; assessments and expectations for Hammerdown Gold Project and Queensway Gold Project, including the timing thereof; New Found Gold's plans to apply for Maritime to cease to be a reporting issuer; the delisting of Maritime Shares and the treatment of the Maritime Options and warrants; and closing of the Shares for Debt Transaction, including receipt of TSXV and NYSE American approvals, and the timing thereof. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "interpreted", "intends", "estimates", "projects", "aims", "suggests", "indicate", "often", "target", "future", "likely", "pending", "potential", "encouraging", "goal", "objective", "prospective", "possibly", "preliminary", and similar expressions, or that events or conditions "will", "would", "may", "can", "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the TSXV and NYSE American, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include risks associated with the Company's ability to complete exploration and drilling programs as expected, possible accidents and other risks associated with mineral exploration operations, the risk that the Company will encounter unanticipated geological factors, risks associated with the interpretation of exploration results and the results of the metallurgical testing program, the possibility that the Company may not be able to secure permitting and other governmental clearances necessary to carry out the Company's exploration plans, the risk that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company's business and prospects. The reader is urged to refer to the Company's Annual Information Form and Management's Discussion and Analysis, publicly available through the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca for a more complete discussion of such risk factors and their potential effects.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274305

November 13, 2025 7:30 AM EST | Source: CEO.CA Technologies Ltd.
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.

Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.

Meet the Executive Shaping the Mining Landscape

'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.

We caught up with Dylan Langille, VP Exploration at White Gold Corp. (TSXV: WGO) (OTCQX: WHGOF) (FSE: 29W). Follow what investors are saying and join our community: https://ceo.ca/wgo

#WhiteGoldCorp #Gold #GoldStocks #Yukon #Mining #Discovery #ResourceStocks #AgnicoEagle

White Gold Corp.
(TSXV: WGO) (OTCQX: WHGOF) (FSE: 29W)

Cannot view this video? Visit:
https://www.youtube.com/watch?v=vR2g1am3FZM

Tune in to 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA here.

Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at [email protected] for further details and opportunities.

About CEO.CA

The leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap investors globally — with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account.

CEO.CA is a wholly owned subsidiary of EarthLabs, Inc.

Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR+ or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274302

Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesity PL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned for once-weekly subcutaneous dosing; IND submission and clinical trial initiation planned for mid-2026 Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for the treatment of retinal diseases in August 2025 Received €2.0M ($2.3M) upfront Achieved €5.5M ($6.5M) research milestone in September 2025 $18.2 million public offering, including full exercise of the over-allotment option, closed on November 12, 2025 Regained compliance with NYSE American listing standards – common stock resumed trading under the symbol "PTN" on November 12, 2025 Teleconference and Webcast to be held on Thursday, November 13, 2025, at 11:00 AM EST PRINCETON, N.J. , Nov. 13, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal first quarter ended September 30, 2025 and provided a corporate update.

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM

PHILADELPHIA, PA / ACCESS Newswire / November 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.

The phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in United States can now expand into additional sites in United Kingdom.

The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service (NHS) capacity and capability standards.

"The United Kingdom regulatory and ethical approval is another major step forward in establishing a global footprint of our novel, non-invasive treatment for BCC of the skin, which we believe represents more than $2 billion in potential market opportunity," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "With clinical development programs now active across United States, Europe, and the Middle East, we are enhancing global patient recruitment and clinical dataset which, among other things, would assist us in designing a robust pivotal program".

SKNJCT-003 Clinical Trial Design
The SKNJCT-003 clinical study is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 90 subjects presenting with BCC of the skin. The study evaluates the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.

The high-dose, 200μg D-MNA, in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.

SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC.

In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev's flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In October 2025, the company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population.

For further information contact:
Carolyn Bonner, President and Acting Chief Financial Officer
(610) 636-0184
[email protected]

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
[email protected]

About Medicus Pharma Ltd.
Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the "MoU") with Helix Nanotechnologies, Inc. ("HelixNano"), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev's flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev's proposed Phase 3 trial design for Teverelix. This milestone supports the Company's clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients

In October 2025, the company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population.

Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SKINJECT™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus's proprietary microneedle array (MNA) delivery platform, the Company's aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

ENGLEWOOD, COLORADO / ACCESS Newswire / November 13, 2025 / Lightwave Logic, Inc. (NASDAQ:LWLG) (the "Company"), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power in a small form factor, announced today that CEO Yves LeMaitre will attend and meet with investors at the 14th Annual Roth Technology Conference from November 18-19, 2025 in New York.

This event will consist of 1-on-1 / small group meetings with approximately 100 companies across the Technology, Media, and Internet verticals.

About ROTH

ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Their full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, Roth is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

About Lightwave Logic, Inc.

Lightwave Logic, Inc. (NASDAQ:LWLG) is a technology platform company pioneering the development of proprietary electro-optic polymers that enable ultra-high-speed data transmission with low power consumption and compact form factors. These materials power next-generation photonic devices for telecommunications, data centers, and emerging AI infrastructure. Visit www.lightwavelogic.com for more information.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, lack of available funding; general economic and business conditions; competition from third parties; intellectual property rights of third parties; regulatory constraints; changes in technology and methods of marketing; delays in completing various engineering and manufacturing programs; changes in customer order patterns; changes in product mix; success in technological advances and delivering technological innovations; shortages in components; production delays due to performance quality issues with outsourced components; those events and factors described by us in Item 1.A "Risk Factors" in our most recent Form 10-K and 10-Q; other risks to which our company is subject; other factors beyond the company's control.

Contacts:

Ryan Coleman or Nick Teves
Alpha IR Group for Lightwave Logic
[email protected]
312-445-2870

SOURCE: Lightwave Logic

SummaryREITs offer compelling value and income, with VNQ yielding 3.8% versus the S&P 500's 1.1%, and trade at historically wide valuation discounts.The current macro environment favors high-quality, undervalued dividend stocks, as falling long-term rates could boost demand for income-generating assets like REITs.REITs demonstrate strong financial health, stable dividends, and sector diversity, making them attractive for both income and potential total return upside.Risks include rising long-term rates and sector-specific challenges, but focusing on quality assets and valuation provides a favorable risk/reward setup for long-term investors.Black Friday Sale 2025: Get 20% Off Tomas Nevesely/iStock via Getty Images

Introduction A few months ago, I had a call with an asset manager about just how tricky this macro environment has become. That may not come as a shock, as we discuss this almost daily. During this call, I

Analyst’s Disclosure:I/we have a beneficial long position in the shares of REXR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

COLUMBUS, Ohio, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company's net loss rate and delinquency rate for the periods indicated:   For the month ended October 31, 2025   For the month ended October 31, 2024   (dollars in millions) End-of-period credit card and other loans $ 17,694     $ 17,915   Average credit card and other loans $ 17,627     $ 17,867   Year-over-year change in average credit card and other loans   (1%)       —%   Net principal losses(1) $ 112     $ 120   Net loss rate(1)   7.5%       7.9%     As of October 31, 2025   As of October 31, 2024   (dollars in millions) 30 days + delinquencies – principal $ 963     $ 1,056   Period ended credit card and other loans – principal $ 15,903     $ 16,451   Delinquency rate   6.1%       6.4%   (1) As a result of hurricanes Helene and Milton we froze delinquency progression for cardholders in Federal Emergency Management Agency identified impact zones for one billing cycle, which resulted in modestly lower Net principal losses and Net loss rate in the fourth quarter of 2024.

Persimmon Plc (OTCPK:PSMMY) Q3 2025 Earnings Call November 13, 2025 4:00 AM EST Company Participants Dean Finch - Group Chief Executive & Executive Director Andrew Duxbury - CFO & Executive Director Conference Call Participants Aynsley Lammin - Investec Bank plc, Research Division Allison Sun - BofA Securities, Research Division Ami Galla - Citigroup Inc., Research Division William Jones - Rothschild & Co Redburn, Research Division Zaim Beekawa - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to Persimmon's Plc Q3 Trading Update Conference Call.

November 13, 2025 7:33 AM EST | Source: Moving iMage Technologies
Fountain Valley, California--(Newsfile Corp. - November 13, 2025) - Moving iMage Technologies, Inc. (NYSE American: MITQ), a leading provider of cutting-edge out-of-home entertainment technology and services for cinema, Esports, stadiums and arenas and other venues, will report Q1 fiscal 2026 results before the market opens on November 14 and host an investor call at 11:00 am ET. Following prepared remarks, management will take investor questions.

Conference Call Details

Date/Time:Friday, November 14 at 11:00am ETToll-Free Number:1-877-407-4018Toll/International Number:1-201-689-8471Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ Link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time.

Telephone Replay

Access ID: 13757170
Replay Dial-In: 1-844-512-2921 or 1-412-317-6671
Replay Expiration: Friday November 28, 2025 at 11:59 p.m. ET

About Moving iMage Technologies (www.movingimagetech.com)

With a focus on innovation, service, and quality, Moving iMage Technologies ("MiT") is a trusted partner in delivering state-of-the-art out-of-home entertainment environments. Founded in 2003, MiT provides products, integrated systems design, custom engineering, proprietary products, software, and installation services for cinemas, screening rooms, postproduction facilities, high-end home theaters, Esports venues, arenas, stadiums, and other entertainment spaces.

MiT manufactures a broad line of digital cinema peripherals in the U.S., including automation systems, projector pedestals/bases, projector lifts, hush boxes, direct-view LED frames, lighting fixtures and dimmers, power management devices, operations software, and Esports platforms. It also distributes and integrates cinema equipment from Barco, Sharp (NEC) Digital Cinema, Christie Digital, LEA Professional, Dolby, GDC, JBL/Crown, LG, Meyer Sound, Q-SYS, QSC, Samsung and others.

MiT's Caddy Products division designs and sells cupholders, concession trays, and venue accessories that enhance concession sales and improve the guest experience.

Follow us on X: @movingimagenews

Follow us on LinkedIn: MiT on LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274295

Aadil Zaman, Partner at Wall Street Alliance Group, says a market pullback is inevitable, with leadership shifting from AI giants to AI enablers like Caterpillar as demand for data-center infrastructure surges.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NLY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Beyond Saving, Philip Mause, and Hidden Opportunities, all are supporting contributors for High Dividend Opportunities. Any recommendation posted in this article is not indefinite. We closely monitor all of our positions. We issue Buy and Sell alerts on our recommendations, which are exclusive to our members.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Study conducted in collaboration with the Alzheimer’s Clinical Trials Consortium

November 13, 2025 07:36 ET

 | Source:

Cognition Therapeutics, Inc.

PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled Phase 2 ‘START’ Study. A number of additional patients are in the final stages of screening and will be randomized if they meet all eligibility requirements. START will assess the safety and activity of zervimesine (CT1812) in participants with mild cognitive impairment (MCI) or early Alzheimer’s disease. Topline results are expected after all participants have completed 18 months of treatment.

“Our clinical operations teams drove impressive enrollment numbers this year based on strong interest from patients and investigators,” stated Lisa Ricciardi, Cognition’s president and CEO. “During the first half of 2025, we made presentations of our Phase 2 results in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies at international conferences and to the START investigators. The interest generated among investigators contributed to the strong enrollment figures, with approximately 50% of the entire study population enrolled during the last six months. We would like to thank our partners at ACTC and our investigators for their commitment, which led to this impressive accomplishment.”

The START study was initiated shortly after Leqembi was granted accelerated approval in the US. Cognition and ACTC made the decision to allow people on stable background therapy with an approved monoclonal antibody therapy to participate. Approximately 15% of participants randomized into START were also receiving infusions of either Leqembi (lecanemab) or Kisunla (donanemab).

Dr. Ryan O'Dell, MD, PhD, assistant professor of psychiatry at the Yale Alzheimer's Disease Research Unit and an investigator in the START study, added, “It’s an exciting time to be involved in Alzheimer’s disease research. With two approved anti-amyloid antibodies, many of our patients finally have new treatment options. But these disease-modifying therapies are only appropriate for some patients, leaving many with MCI and mild dementia due to Alzheimer’s disease, and the entire spectrum of people with more severe disease, without access to these novel treatments. The START study was a unique opportunity to investigate an experimental oral drug with a mechanism that is unlike that of the currently approved immunotherapeutics, with the potential to treat a broader segment of the Alzheimer’s patient community. And the prospect of combination therapy is particularly exciting for those patients receiving background Leqembi or Kisunla infusions as part of their clinical care.”

“We expect zervimesine’s oral dosing and safety profile, with no increased risk of ARIA or need for serial imaging, to reduce the burden on patients and healthcare providers,” concluded Anthony O. Caggiano, Cognition’s chief medical officer. “We believe zervimesine has the potential to be an important part of the Alzheimer’s disease treatment arsenal for patients with early, mild and moderate Alzheimer’s disease.”

About the START Study
The START Study (NCT05531656) is designed to measure the efficacy and tolerability of once-daily oral zervimesine in individuals with mild cognitive impairment (MCI) or early Alzheimer’s disease who have elevated Aβ as measured by PET or CSF. Participants are randomized to receive zervimesine or placebo for 18 months. The study will measure cognition and executive function using validated tools including the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and ADAS-Cog rating scales. Biomarkers and safety findings will also be assessed.

The START Study is supported by an $81 million grant from the National Institute of Aging (NIA) at the National Institutes of Health (R01AG065248). The study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC), an NIA-funded (grant number U24AG057437) clinical trial network of 35 leading academic sites with expertise in clinical trials in Alzheimer’s disease.

About Zervimesine (CT1812)
Zervimesine (CT1812) is an investigational, oral, once-daily pill in development for the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain – Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person’s ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer’s and DLB. Zervimesine has been generally well tolerated in clinical studies to date.

The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START Study (NCT05531656) in early Alzheimer’s disease is ongoing. We believe zervimesine can regulate pathways that are impaired in these diseases through its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference call, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements related to our clinical studies of zervimesine (CT1812), including our Phase 2 START study, and any analysis of the results or timing of the results therefrom; any expected or implied benefits or results of zervimesine, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of global political changes and global economic conditions, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

This press release was published by a CLEAR® Verified individual.

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

Copyright 2025 Zacks Investment Research 101 N Wacker Drive, Floor 15, Chicago, IL 60606

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.

Visit Performance Disclosure for information about the performance numbers displayed above.

Visit www.zacksdata.com to get our data and content for your mobile app or website.

Real time prices by BATS. Delayed quotes by Sungard.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.

This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.

Nissan Motor is considering a joint vehicle and powertrain development with Honda Motor in the United States, Nissan CEO Ivan Espinosa told the Nikkei business daily on Thursday.

UniCredit's efforts in relation to its Russian unit consist, on one side, in trying to comply with international sanctions and, on the other, in avoiding moves that could prompt Moscow to seize the bank, CEO Andrea Orcel said on Thursday.

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

Preferred Bank (PFBC - Free Report) : This banking products and services company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.

Weatherford International plc (WFRD - Free Report) : This energy services company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.6% over the last 60 days.

Insulet Corporation (PODD - Free Report) : This insulin delivery systems company has seen the Zacks Consensus Estimate for its current year earnings increasing 6.5% over the last 60 days.

PRA Group, Inc. (PRAA - Free Report) : This financial services company has seen the Zacks Consensus Estimate for its current year earnings increasing 9.9% over the last 60 days.

Alexander’s, Inc. (ALX - Free Report) : This real estate investment trust has seen the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

-

Alarm.com's new Wi-Fi spotlight camera delivers vivid 4MP video with color night vision and proactive threat prevention

TYSONS, Va.--(BUSINESS WIRE)--Alarm.com (Nasdaq: ALRM), the leading platform for intelligently connected properties, launches the ADC-V730, the company's first Wi-Fi spotlight camera. The V730 combines vivid 4MP video resolution with spotlight-enabled color night vision and proactive deterrence features to create a first line of defense against unwanted activity.

Built-in Video Analytics on the V730 detect people, animals, or vehicles, triggering the integrated spotlight to automatically illuminate the area while activating Perimeter Guard® and AI Deterrence (AID) protocols. AID delivers AI-generated verbal responses that give the impression of live monitoring to deter threats in real-time.

"The V730 combines our most advanced video capabilities with intelligent deterrence in a single, easy-to-deploy solution," said Dan Kerzner, President of Platforms Business at Alarm.com. "This camera gives our service providers a powerful tool that customers can immediately see and appreciate—vivid 4MP video, color night vision, and AI-powered deterrence that works around the clock."

Proactive Technology That Works

The V730 delivers focused protection where it matters most. When Perimeter Guard® detects potential threats, the camera's LED flashes while the loudspeaker delivers automated warnings or enables manual talk-down communication. Combined with AID and the camera's 129° horizontal field of view for comprehensive coverage, this approach provides multiple layers of protection.

Streamlined Deployment for Service Providers

For service providers, the V730 delivers operational advantages that improve the technician experience. Bluetooth® Enrollment technology allows technicians to connect cameras quickly from mobile devices, supporting saved networks with active error handling. This streamlined process enables faster installations, more time with the customer, and fewer service callbacks while also supporting DIY customers who prefer self-installation.

Professional-Grade Performance

The V730 features dual-band Wi-Fi connectivity for flexible placement, two-way audio for real-time interaction, and microSD recording compatibility supporting cards up to 1TB for continuous 24/7 recording. NDAA-compliant construction ensures compatibility with commercial and government installations, while integration with Alarm.com's professionally monitored infrastructure enables Visual Verification of Intrusion Alarms and Proactive Remote Video Monitoring services.

The ADC-V730 is available now through Alarm.com service providers across North America and will be coming to international providers soon. For more information about the ADC-V730 and Alarm.com's complete video security ecosystem, visit www.alarm.com.

About Alarm.com

Alarm.com is the leading platform for intelligently connected properties. Millions of homeowners and businesses rely on Alarm.com’s technology to secure, monitor, and manage their environments from anywhere. Our comprehensive suite of solutions—including security, video surveillance, access control, active shooter detection, intelligent automation, energy management, and wellness—is delivered exclusively through a trusted network of thousands of professional service providers and commercial integrators across North America and worldwide. Alarm.com’s common stock is traded on Nasdaq under the ticker symbol ALRM. Alarm.com delivers serious security for serious people. To learn more, visit www.alarm.com.

More News From Alarm.com Holdings, Inc.

Back to Newsroom

SummaryDorchester Minerals remains a buy, supported by a debt-free balance sheet, strong fundamentals, and a ~12% dividend yield.DMLP's solid cash flows and conservative financial structure position it well, despite recent earnings declines due to lower oil prices and higher non-cash expenses.Macro catalysts, including OPEC's latest moves, Russian sanctions, and potential US rate cuts, could drive oil price recovery and benefit DMLP's future growth.Risks persist if DMLP's valuation declines further, but the company is also ready to capitalize on higher valuations and expansion opportunities. John Drost/iStock via Getty Images

Introduction Back when I last covered Dorchester Minerals (DMLP), I pointed out how their strong financial health, low valuation, and attractive dividend yield, with their DMLP's multi-basin acquisitions and debt-free balance sheet, position them well to

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in DMLP over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

For a business built on orthopaedics and wound care, Smith & Nephew PLC (LSE:SN) has given investors a fair bit of whiplash.

Its third-quarter update sent the shares down about 10% after organic revenue growth came in weaker than hoped and, crucially, slowed from the second quarter despite earlier guidance that it would accelerate.

UBS says the numbers were not disastrous in themselves, but sentiment had run ahead of reality and a cluster of headwinds now threatens to slow margin progress next year.

The broker still thinks the company can manage 4–5% revenue growth and eventually lift margins towards 21%.

Even so, it sees some risk to 2026 expectations and argues the shares now sit roughly where they should, trading close to their three to five-year average relative to the wider medical devices sector.

Attention turns to the Capital Markets Day in London on 8 December. Investors are hoping for a fresh mid-term guidance range, probably centred on mid-single digit organic revenue growth and a return to operating margins above 22%, the level seen before the pandemic.

UBS cautions that any bolder revenue ambition would likely be viewed with scepticism, so a measured approach could land better. For 2026, its own model assumes 4% organic growth and a modest 40 basis-point margin lift.

Forecast tweaks are minor. Revenue estimates for 2025 to 2029 are largely unchanged, while margins for 2025 rise on the back of management’s comments, pushing adjusted operating profit up by 3%.

Forecasts ease slightly for 2026 and 2027, although expected cost savings later in the decade lift outer-year numbers. A recently announced $500 million buyback, followed by $250 million a year thereafter, nudges adjusted earnings per share up by 5–10%.

UBS has inched its valuation up to £12.90 from £12.50, based on a discounted cash flow model. That implies about 15 times 2026 earnings, a discount of 15–20% to the sector and in line with historical norms.

With only a sliver of upside to its target price, the 'neutral' rating stays put.

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates. “Both tibulizumab studies advanced during the quarter,” said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Z.